Effect of honey on CYP3A4 enzyme and P-glycoprotein activity in healthy human volunteers

Iranian Journal of Pharmacology and Therapeutics

Volumn 6, Issue 2, 2007, Pages 171-176

  Thomas, Vinod ^a   Ramasamy, Kesavan ^a   Sundaram, Rajan ^a   Chandrasekaran, Adithan ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Carbamazepine; CYP3A4; Digoxin; Honey; P glycoprotein

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450 3A4; DIGOXIN; GLYCOPROTEIN P;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME ACTIVITY; FOOD DRUG INTERACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HONEY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MEDICAL RESEARCH; NORMAL HUMAN; RADIOIMMUNOASSAY; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 55949085571     PISSN: 17352657     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. White JW Jr. Honey. Adv Food Res1978; 24: 287-374.
2. Honey Stix [homepage on the internet]: Nutrition Info.: Therapeutic studies of honey: Honey health and therapeutic qualities (article provided by National Honey Board). Available from: http://www.honeystix.com/honeystix/ compendium.pdf. Accessed on December 18, 2006.
3. Evans AM. Influence of dietary components on the gastrointestinal metabolism and transport of drugs. Ther Drug Monit 2000;22:131-6.
4. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001; 40:159-68.
5. Koumaravelou K, Adithan C, Shashindran CH, Asad M, Abraham BK. Influence of honey on orally and intravenously administered diltiazem kinetics in rabbits. Indian J Exp Biol 2002;40:1164-8.
6. Koumaravelou K, Adithan C, Shashindran CH, Asad M, Abraham BK. Effect of honey on carbamazepine kinetics in rabbits. Indian J Exp Biol 2002; 40: 560-3.
7. Malhotra S, Garg SK, Dixit RK. Effect of concomitantly administered honey on the pharmacokinetics of carbamazepine in healthy volunteers. Methods Find Exp Clin Pharmacol 2003;25:537-40.
8. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ et al. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10, 11-epoxide formation. Biochem Pharmacol 1994; 47:1969-79.
9. Spina E, Arena D, Scordo MG, Fazio A, Pisani F, Perucca E. Elevation of plasma carbamazepine concentrations by ketoconazole in patients with epilepsy. Ther Drug Monit 1997;19:535-8.
10. Pan G, Wang G, Fawcett P. The role of P-glycoprotein in the intestinal barrier. Asian J Drug Metab Pharmacokinet 2002;2:69-76.
11. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1(P-glycoprotein): Recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75 :13-33.
12. de Lannoy AI, Silverman M. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 1992; 189: 551-7.
13. Deferme S, Van GJ, Augustijns P. Inhibitory effect of fruit extracts on P-glycoprotein related efflux carriers: An in vitro screening. J Pharm Pharmacol 2002; 54:1213-9.
14. Tian R, Koyabu N, Takanaga H, Matsuo H, Ohtani H, Sawada Y. Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates, Pharm Res 2002; 19: 802-9.
15. Becquemont L, Verstuyft C, Kerb R, Brinkmann U, Lebot, M, Jaillon P et al. Effect of grapefruit juice on digoxin pharmacokinetics in humans, Clin Pharmacol Ther 2001; 70: 311-6.
16. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66: 338-45.
17. Owen A, Pirmohamed M, Tettey JN, Morgan P, Chadwick D, Park BK. Carbamazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol 2001; 51:345-9.
18. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104:147-53.
19. Gerson B, Bell F, Chan S. Antiepileptic agents - primidone, phenobarbital, phenytoin and carbamazepine by reversed-phase liquid chromatography. Clin Chem 1984; 30:105-8.
20. Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002; 34: 234-8.
21. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997; 99:2545-53.
22. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ et al. St John's Wort induces intestinal P-glycoprotein / MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000; 68:598-604.
23. Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S, Schiff PL, Strom SC. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos 2000; 28:1270-3.
24. Ishihara K, Kushida H, Yuzurihara M, Wakui Y, Yanagisawa T, Kamei H et al. Interaction of drugs and Chinese herbs: Pharmacokinetic changes of tolbutamide and diazepam caused by extract of Angelica dahurica, J Pharm Pharmacol 2000; 52:1023-9.
25. Guo LQ, Taniguchi M, Chen QY, Baba K, Yamazoe Y. Inhibitory potential of herbal medicines on human cytochrome P450-mediated oxidation: Properties of umbelliferous or citrus crude drugs and their relative prescriptions. Jpn J Pharmacol 2001; 85: 399-408.
26. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000; 7: 273-82.
27. Chearwae W, Anuchapreeda S, Nandigama K, Ambudkar SV, Limtrakul P. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder, Biochem Pharmacol 2004; 68: 2043-52.
28. Tankanow R, Tamer HR, Streetman DS, Smith SG, Welton J L, Annesley T et al. Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha), J Clin Pharmacol 2003; 43: 637-42.
29. Kim SW, Kwon HY, Chi DW, Shim JH, Park JD, Lee YH et al. Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg(3). Biochem Pharmacol 2003; 65: 75-82.
30. Sadzuka Y, Sugiyama T, Sonobe T. Efficacies of tea components on doxorubicin induced antitumor activity and reversal of multidrug resistance. Toxicol Lett 2000; 114:155-62.
31. Zhang S, Morris M E. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 2003; 304:1258-67.
32. Velpandian T, Jasuja R, Bhardwaj RK, Jaiswal J, Gupta SK. Piperine in food: interference in the pharmacokinetics of phenytoin. Eur J Drug Metab Pharmacokinet 2001; 26: 241-7.
33. Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M et al. Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 2000; 68: 6-12.